Form 4: Vir Biotech CFO Transfers Shares for Estate Planning

Vir Biotechnology's EVP & CFO, Jason O'Byrne, transferred 2,500 shares of common stock to a family trust for estate planning purposes.

Summary

• Jason O'Byrne, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (VIR), reported a transaction involving 2,500 shares of common stock.
• The transaction, dated March 20, 2026, was a transfer without consideration for estate planning purposes, indicated by transaction code 'J'.
• 2,500 shares were transferred from O'Byrne's direct beneficial ownership to indirect beneficial ownership.
• Following the transfer, O'Byrne directly owns 160,115 shares of common stock.
• The 2,500 shares are now indirectly held in the O'Byrne Family Trust, of which O'Byrne and his spouse are trustees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a personal financial decision by an executive rather than an indicator of company performance or strategic direction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those for estate planning, are common and typically do not reflect a change in the company's operational performance or outlook. Such transfers are personal financial decisions by executives.

Related Party Transactions

• Transfer of 2,500 shares of common stock from direct ownership to the O'Byrne Family Trust, of which the reporting person and his spouse are trustees.

Stakeholder Impact

• Shareholders: No material impact on company operations or valuation; this is a change in the form of beneficial ownership for an executive, not a sale or purchase in the open market.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction for estate planning purposes, which does not reflect on the operational performance or strategic direction of Vir Biotechnology. It is a personal financial decision by the EVP & CFO and does not provide a basis for a change in investment recommendation.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, Stock Transfer, Estate Planning, Jason O'Byrne